BCG vaccination strategies against tuberculosis: updates and perspectives.
Hum Vaccin Immunother
; 17(12): 5284-5295, 2021 12 02.
Article
in English
| MEDLINE | ID: covidwho-1746993
ABSTRACT
Bacillus Calmette-Guérin (BCG) is the only licensed vaccine against tuberculosis (TB). However, BCG has variable efficacy and cannot completely prevent TB infection and transmission. Therefore, the worldwide prevalence of TB calls for urgent development of a more effective TB vaccine. In the absence of other approved vaccines, it is also necessary to improve the efficacy of BCG itself. Intravenous (IV) BCG administration and BCG revaccination strategies have recently shown promising results for clinical usage. Therefore, it is necessary for us to revisit the BCG vaccination strategies and summarize the current research updates related to BCG vaccination. This literature review provides an updated overview and perspectives of the immunization strategies against TB using BCG, which may inspire the following research on TB vaccine development.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Tuberculosis
/
Tuberculosis Vaccines
/
Mycobacterium bovis
/
Mycobacterium tuberculosis
Type of study:
Observational study
/
Prognostic study
/
Reviews
Topics:
Vaccines
Limits:
Humans
Language:
English
Journal:
Hum Vaccin Immunother
Year:
2021
Document Type:
Article
Affiliation country:
21645515.2021.2007711
Similar
MEDLINE
...
LILACS
LIS